ArticleClinical kidney journal2025
Fibrillary glomerulonephritis: an observational study of clinical-pathological features and outcomes in patients from a multi-institutional cohort.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DNAJB9 in Fibrillary Glomerulonephritis: Diagnostic Biomarker, Putative Autoantigen, or Disease-Associated Scaffold? A Case-Based Narrative Review.Life (Basel, Switzerland) · 2026Article
- Clinicopathologic features and outcomes of patients with DNAJB9-positive fibrillary glomerulonephritis.Clinical kidney journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibrillary glomerulonephritis (FGN) is a rare glomerulopathy characterized by randomly arranged fibrils within the mesangium and glomerular basement membrane. It has poor renal outcomes and no specific treatment. This retrospective study aimed to identify clinical-pathological predictors of outcomes in a multi-institutional cohort with histopathology performed at a single centre in the UK. Methods: Patients with biopsy proven FGN between 2015 and 2024 were identified using the Cambridge University Hospitals (CUH) histopathology database. Clinical data, including demographics, comorbidities, laboratory parameters, treatments and outcomes, were compared with findings from four other studies. Histological characteristics and DNAJB9 staining, where available, were analysed. Results: Thirty-five patients with FGN (2.8:1 female-to-male ratio) with a mean age of 62.8 years were identified. Autoimmune diseases, diabetes mellitus (DM) and malignancy (solid organ and haematological) were present in 28.5%, 34.2% and 20%, respectively. Nephrotic-range proteinuria was present in 58.8% and renal dysfunction in 91.4% at presentation. The most common histological pattern was mesangial proliferative/sclerosing followed by diffuse proliferative (DPGN). DNAJB9 staining was positive in all 13 tested patients. At a median 39 months follow-up, 51% progressed to end-stage renal disease (ESRD). Female sex, proteinuria and DPGN were significant predictors of ESRD on multivariate analysis. Although rituximab was associated with non-progression of disease, immunosuppression showed no statistically significant impact on outcomes. Conclusion: FGN is strongly associated with malignancy, autoimmune disease and DM. Prognosis remains poor, with progression to ESRD significantly influenced by proteinuria, DPGN and female sex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.